Cargando…
The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. Pemetrexed is an antifolate compound with the ability to inhibit enzymes (TS, DHFR and GARFT) involved in pyrimidine and purine synthesis. The objective of th...
Autores principales: | Kucharczyk, Tomasz, Krawczyk, Paweł, Powrózek, Tomasz, Kowalski, Dariusz M., Ramlau, Rodryg, Kalinka-Warzocha, Ewa, Knetki-Wróblewska, Magdalena, Winiarczyk, Kinga, Krzakowski, Maciej, Milanowski, Janusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681747/ https://www.ncbi.nlm.nih.gov/pubmed/26277606 http://dx.doi.org/10.1007/s12253-015-9966-z |
Ejemplares similares
-
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014) -
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021) -
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022) -
Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
por: Powrózek, Tomasz, et al.
Publicado: (2014) -
Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)